A Decade of Innovation

Over the past 10 years, we have made it our mission to serve the psychiatric community of more than 14 million people living with bipolar disorder and schizophrenia in the United States. We continue to investigate some of the world's most serious mental disorders to help improve the lives of patients with these conditions.

Bipolar Depression*

Approximate

29M

Worldwide
Approximate

12.6M

United States

Schizophrenia*

Approximate

20M

Worldwide
Approximate

1M

United States

Our Medicines

LATUDA is a prescription medicine used to treat adults and adolescents (13 to 17 years) with schizophrenia. Alone to treat adults, children and teens (10 to 17 years) with depressive episodes that happen with bipolar I disorder (bipolar depression). With the medicine lithium or valproate to treat adults with depressive episodes that happen with bipolar I disorder (bipolar depression).

Please read the full Prescribing Information, including Boxed Warning for Latuda.

For HCP information, please visit: Visit Latuda HCP site

For patient information, please visit: Visit Latuda patient site

What is
Sunovion Answers?

We believe in putting people first, which is why we created Sunovion Answers. Our caring and skilled team is available to provide knowledge and resources to help patients, caregivers, family members, or providers. We’re committed to finding solutions and connecting people to the information they need.

Specialists are available anytime between 8AM and 12 midnight (ET): 1-855-552-8832

A woman wearing glasses taking notes from her online research.

Our Psychiatry Pipeline

We are committed to the investigation and discovery of novel therapies to help people living with serious mental health conditions. From identifying new pathways to treat schizophrenia to advancing new candidates for bipolar depression, our work never stops.

Therapeutic Area

Candidate

Indication/Target

Phase

 

Therapeutic Area

Indication/Target

Candidate